DK3290513T3 - Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering - Google Patents

Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering Download PDF

Info

Publication number
DK3290513T3
DK3290513T3 DK17186206.3T DK17186206T DK3290513T3 DK 3290513 T3 DK3290513 T3 DK 3290513T3 DK 17186206 T DK17186206 T DK 17186206T DK 3290513 T3 DK3290513 T3 DK 3290513T3
Authority
DK
Denmark
Prior art keywords
compositions
preventing
methods
aav vector
vector aggregation
Prior art date
Application number
DK17186206.3T
Other languages
English (en)
Inventor
John Fraser Wright
Guang Qu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3290513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK3290513T3 publication Critical patent/DK3290513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
DK17186206.3T 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering DK3290513T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57599704P 2004-06-01 2004-06-01
US63922204P 2004-12-22 2004-12-22
EP05755269.7A EP1751275B1 (en) 2004-06-01 2005-06-01 Compositions and methods to prevent aav vector aggregation

Publications (1)

Publication Number Publication Date
DK3290513T3 true DK3290513T3 (da) 2022-12-12

Family

ID=35462907

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05755269.7T DK1751275T3 (da) 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forebyggelse af aggregering af aav-vektorer
DK17186206.3T DK3290513T3 (da) 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05755269.7T DK1751275T3 (da) 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forebyggelse af aggregering af aav-vektorer

Country Status (10)

Country Link
US (4) US7704721B2 (da)
EP (3) EP4170024A1 (da)
JP (5) JP2008501339A (da)
BR (1) BRPI0511764B8 (da)
CA (1) CA2569244C (da)
DK (2) DK1751275T3 (da)
ES (2) ES2647477T3 (da)
HU (2) HUE035418T2 (da)
MX (3) MXPA06014030A (da)
WO (1) WO2005118792A1 (da)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2099485B1 (en) * 2006-11-03 2018-03-21 AlphaVax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
US8067241B2 (en) * 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
MX340102B (es) * 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
CA2829774C (en) * 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
CA2856137A1 (en) 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
DK2790737T3 (da) 2011-12-12 2019-03-18 Childrens Hospital Philadelphia Kommerciel storskala lentivirusvektor-fremstillingssystem og vektorer fremstillet derved
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
PL3010537T3 (pl) * 2013-06-17 2019-03-29 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Sposoby zapobiegania agregacji komponentów wirusowych
WO2015080223A1 (ja) 2013-11-29 2015-06-04 タカラバイオ株式会社 アデノ随伴ウイルスの定量方法
EP3851537B1 (en) 2014-04-25 2023-12-27 Genethon Treatment of hyperbilirubinemia
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2016004319A1 (en) * 2014-07-02 2016-01-07 University Of Florida Research Foundation, Inc. Compositions and methods for purifying recombinant adeno-associated virus
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
CN112410339A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
RU2716422C2 (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
EP3245218A4 (en) * 2015-01-13 2018-10-03 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
KR102877920B1 (ko) 2015-11-16 2025-10-30 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
EP3387117B1 (en) * 2015-12-11 2022-11-23 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
PT3436593T (pt) 2016-03-28 2023-01-31 Ultragenyx Pharmaceutical Inc Métodos de inativação pelo calor de adenovírus
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
CA3252099A1 (en) 2016-05-18 2025-06-05 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
US20190284576A1 (en) * 2016-07-21 2019-09-19 Spark Therapeutics, Inc. SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBY
CA3034527A1 (en) 2016-08-23 2018-03-01 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
IL319481A (en) 2016-09-12 2025-05-01 Inst Nat Sante Rech Med Variants of acid alpha-glucosidase and their uses
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
JP7051132B2 (ja) 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
ES2981519T3 (es) 2016-11-04 2024-10-09 Takeda Pharmaceuticals Co Formulaciones de virus adeno-asociados
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US10294452B2 (en) * 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
WO2018141865A1 (en) 2017-02-01 2018-08-09 Centre National De La Recherche Scientifique Particles and compositions comprising the same for transfection
WO2018162748A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2019018342A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. NETWORK EQUIPMENT TRACK GUIDE SYSTEM
KR102850887B1 (ko) 2017-08-03 2025-08-28 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN119242711A (zh) 2017-10-16 2025-01-03 沃雅戈治疗公司 肌萎缩性侧索硬化症（als）的治疗
EP3707264A1 (en) * 2017-11-08 2020-09-16 Avexis Inc. Means and method for preparing viral vectors and uses of same
WO2019113202A1 (en) * 2017-12-05 2019-06-13 Applied Genetic Technologies Corporation Formulation optimization for viral particles
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
JP7467356B2 (ja) 2018-02-07 2024-04-15 ジェネトン ハイブリッド調節要素
WO2019173434A1 (en) 2018-03-06 2019-09-12 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
WO2019210137A1 (en) 2018-04-27 2019-10-31 Voyager Therapeutics, Inc. Methods for measuring the potency of aadc viral vectors
BR112020023082A2 (pt) 2018-05-15 2021-02-09 Voyager Therapeutics, Inc. composições e métodos para o tratamento de doença de parkinson
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
US12228571B2 (en) 2018-06-08 2025-02-18 Novartis Ag Cell-based assay for measuring drug product potency
WO2020006458A1 (en) 2018-06-29 2020-01-02 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
CA3103740A1 (en) * 2018-06-29 2020-01-02 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
MX2020013953A (es) * 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
WO2020023612A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
JP7548899B2 (ja) 2018-08-08 2024-09-10 ジェネトン 糖原病ｉｉｉの処置のためのミニｇｄｅ
JP2021533757A (ja) * 2018-08-10 2021-12-09 リジェネクスバイオ インコーポレイテッド 組換えａａｖ生成のためのスケーラブルな方法
EP3840785A4 (en) 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBERIAN OPTIC ATROPHY
CA3114621A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
AU2020208467A1 (en) 2019-01-18 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing AAV particles
US12377170B2 (en) 2019-02-26 2025-08-05 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy
JP7541027B2 (ja) 2019-04-08 2024-08-27 ジェネトン 筋肉発現のためのハイブリッドプロモーター
EP3956354A1 (en) 2019-04-19 2022-02-23 Genethon Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
MX2021012564A (es) * 2019-04-19 2022-01-18 Regenxbio Inc Formulaciones y métodos de vectores de virus adenoasociados.
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
KR20220035937A (ko) 2019-07-25 2022-03-22 노파르티스 아게 조절 가능한 발현 시스템
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
US11155835B2 (en) 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
EP4017871B1 (en) 2019-08-21 2024-01-17 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
TW202122582A (zh) 2019-08-26 2021-06-16 美商航海家醫療公司 病毒蛋白之控制表現
JP2022552262A (ja) 2019-10-07 2022-12-15 リジェネックスバイオ インコーポレイテッド アデノ随伴ウイルスベクター医薬組成物および方法
CN114555808A (zh) 2019-10-22 2022-05-27 吉尼松公司 嵌合多肽及其用途
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
BR112022016596A2 (pt) 2020-02-21 2022-11-16 Akouos Inc Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
US20230212528A1 (en) * 2020-06-02 2023-07-06 Janssen Biotech, Inc. Materials and methods for viral purification
US20230295656A1 (en) 2020-08-06 2023-09-21 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
AU2021320395A1 (en) * 2020-08-07 2023-04-13 Janssen Biotech, Inc. Formulations for highly purified viral particles
WO2022043280A1 (en) 2020-08-24 2022-03-03 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
KR20230078805A (ko) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. 아데노-연관 바이러스의 농축 공정
US20240067942A1 (en) 2020-12-09 2024-02-29 Genethon Lysosomal acid lipase variants and uses thereof
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202246516A (zh) 2021-03-03 2022-12-01 美商航海家醫療公司 病毒蛋白之控制表現
EP4333896A4 (en) * 2021-05-07 2025-03-19 Board of Regents, The University of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vectors and other molecules
CN117897492A (zh) 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
CN117980484A (zh) 2021-09-16 2024-05-03 诺华股份有限公司 新颖的转录因子
JP2023059858A (ja) 2021-10-15 2023-04-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
JP2024539123A (ja) 2021-10-25 2024-10-28 ノバルティス アーゲー アデノ随伴ウイルス（ａａｖ）送達を改善する方法
WO2023175584A1 (en) 2022-03-17 2023-09-21 Innoskel Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
EP4514839A1 (en) 2022-03-17 2025-03-05 Innoskel Hybrid promoters and their use in osteolysis syndrome
JP2025517628A (ja) 2022-05-06 2025-06-10 ノバルティス アーゲー 新規の組換えａａｖ ｖｐ２融合ポリペプチド
CA3252764A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale GDE truncated at the N-terminal level for the treatment of type III glycogen storage disease
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物
WO2025003477A1 (en) 2023-06-29 2025-01-02 Genethon N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
EP4606892A1 (en) 2024-02-23 2025-08-27 Merck Patent GmbH Methods for the production of viral particles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1080218A1 (en) * 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
CA2399321C (en) * 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US7326555B2 (en) * 2002-05-14 2008-02-05 Merck & Co., Inc. Methods of adenovirus purification

Also Published As

Publication number Publication date
ES2932278T3 (es) 2023-01-17
US20110076744A1 (en) 2011-03-31
ES2647477T3 (es) 2017-12-21
EP1751275B1 (en) 2017-08-16
DK1751275T3 (da) 2017-11-27
JP2019058177A (ja) 2019-04-18
HUE060433T2 (hu) 2023-03-28
EP4170024A1 (en) 2023-04-26
JP5769650B2 (ja) 2015-08-26
EP3290513B1 (en) 2022-09-07
EP3290513A1 (en) 2018-03-07
MXPA06014030A (es) 2007-10-08
BRPI0511764A (pt) 2008-01-08
US20060035364A1 (en) 2006-02-16
CA2569244C (en) 2017-02-14
BRPI0511764B1 (pt) 2017-10-24
JP2016195587A (ja) 2016-11-24
CA2569244A1 (en) 2005-12-15
US20160083694A1 (en) 2016-03-24
EP1751275A1 (en) 2007-02-14
HUE035418T2 (en) 2018-05-02
EP1751275A4 (en) 2008-01-23
US9051542B2 (en) 2015-06-09
BRPI0511764B8 (pt) 2021-05-25
JP2012143233A (ja) 2012-08-02
US20170247664A1 (en) 2017-08-31
JP2008501339A (ja) 2008-01-24
US7704721B2 (en) 2010-04-27
MX360727B (es) 2018-11-14
MX2019006353A (es) 2022-06-27
WO2005118792A1 (en) 2005-12-15
JP2014111625A (ja) 2014-06-19

Similar Documents

Publication Publication Date Title
DK3290513T3 (da) Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering
NO20200670A1 (no) Sammensetninger og fremgangsmåter for modulering av hemostase
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1730301T3 (da) Fremgangsmåder og sammensætninger til at analysere AHASL-gener
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
ATE496535T1 (de) Fungizidzusammensetzungen
DK1677735T3 (da) Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
EP1799260A4 (en) ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
DK2377922T3 (da) PDX1-eksprimerende endoderm
ATE497696T1 (de) Flüssige pestizidzusammensetzungen
FI20040156A0 (fi) Hydraulivasara
EP1788047A4 (en) WATER REPELLENT / OIL-REPELLING COMPOSITION
DK1858864T3 (da) Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
EP1724635A4 (en) VIDEO PROJECTOR
EP1795833A4 (en) REFRIGERATION APPARATUS
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer
JP2006522780A5 (ja) 液状形態及び凍結乾燥形態の免疫グロブリンｇ組成物用安定化配合物
DK3309233T4 (da) Sammensætninger omfattende hfc-1234yf og hfc-152a
DK1677949T3 (da) Antibelægningssammensætninger og fremgangsmåder til udvælgelse af disse
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DK1774566T3 (da) Sammensætninger til afgivelse af kviksölv og fremgangsmåde til fremstilling deraf
ATE498181T1 (de) Monoblock kühleinrichtungskomponente